BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taylor EB, Sasser JM, Maeda KJ, Ryan MJ. Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus. Am J Physiol Renal Physiol 2019;317:F1274-84. [PMID: 30892934 DOI: 10.1152/ajprenal.00616.2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Itani HA, Evans LC. Editorial: Inflammation in hypertensive disorders. Front Physiol 2022;13:1085856. [PMID: 36699690 DOI: 10.3389/fphys.2022.1085856] [Reference Citation Analysis]
2 Yuan Y, Kolios AGA, Liu Y, Zhang B, Li H, Tsokos GC, Zhang X. Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med 2022:S1471-4914(22)00106-X. [PMID: 35624009 DOI: 10.1016/j.molmed.2022.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Hengel FE, Benitah J, Wenzel UO. Mosaic theory revised: inflammation and salt play central roles in arterial hypertension. Cell Mol Immunol 2022;19:561-576. [DOI: 10.1038/s41423-022-00851-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang F, Wang S, He B, Liu H, Wang X, Li C, Peng P, Zhao J, Zang Y. Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs. Int Immunopharmacol 2021;97:107663. [PMID: 33887578 DOI: 10.1016/j.intimp.2021.107663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Madhur MS, Elijovich F, Alexander MR, Pitzer A, Ishimwe J, Van Beusecum JP, Patrick DM, Smart CD, Kleyman TR, Kingery J, Peck RN, Laffer CL, Kirabo A. Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Circ Res 2021;128:908-33. [PMID: 33793336 DOI: 10.1161/CIRCRESAHA.121.318052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
6 McClung DM, Kalusche WJ, Jones KE, Ryan MJ, Taylor EB. Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus. Physiol Rep 2021;9:e14734. [PMID: 33527772 DOI: 10.14814/phy2.14734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang J, Huang Y. Low-dose IL-2 in the treatment of immune-related diseases. Eur J Inflamm 2021;19:205873922110399. [DOI: 10.1177/20587392211039935] [Reference Citation Analysis]
8 Dent EL, Broome HJ, Sasser JM, Ryan MJ. Blood pressure and albuminuria in a female mouse model of systemic lupus erythematosus: impact of long-term high salt consumption. Am J Physiol Regul Integr Comp Physiol 2020;319:R448-54. [PMID: 32813539 DOI: 10.1152/ajpregu.00070.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ishimwe JA, Garrett MR, Sasser JM. 1,3-Butanediol attenuates hypertension and suppresses kidney injury in female rats. Am J Physiol Renal Physiol 2020;319:F106-14. [PMID: 32508113 DOI: 10.1152/ajprenal.00141.2020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
10 Stremska ME, Dai C, Venkatadri R, Wang H, Sabapathy V, Kumar G, Jose S, Mohammad S, Sung SJ, Fu SM, Sharma R. IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. J Autoimmun 2019;102:133-41. [PMID: 31103267 DOI: 10.1016/j.jaut.2019.05.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]